Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Phospholipase Inhibitor
A3373 is a novel inhibitor of Phospholipase D1 (PLD1) and Phospholipase D2 (PLD2), exhibiting IC50 values of 325 nM and 15.15 μM, respectively. This compound effectively inhibits lipopolysaccharide (LPS)-induced immune responses, making it valuable for research in autoimmune arthritis, bone demineralization, and osteoclastogenesis. Its action on phospholipase pathways underscores its potential for studying related inflammatory and osteological disorders. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-13 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound exhibits strong inhibitory activity, making it a valuable tool for investigating neurodegenerative diseases. It serves as a potential therapeutic candidate for research focused on the modulation of inflammatory processes associated with neurodegeneration. -
aSMase Inhibitor
C10 Bisphosphonate is a potent inhibitor of acid sphingomyelinase (aSMase) with an IC50 value of 0.02 μM in rat models. This compound demonstrates significant effectiveness in preventing Dexamethasone-induced apoptosis and mitigating platelet-activating factor (PAF)-induced pulmonary edema. C10 Bisphosphonate serves as a valuable tool for research focused on pulmonary edema and related cellular mechanisms. -
Phospholipase Inhibitor
Lp-PLA2-IN-3 is a powerful inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), exhibiting an IC50 of 14 nM against recombinant human Lp-PLA2 (rhLpPLA2). This compound demonstrates significant biological activity in modulating inflammation and atherosclerosis-associated pathways. It is applicable in research focused on cardiovascular diseases and other conditions linked to phospholipid metabolism. -
Phospholipase Inhibitor
PDDC is a selective phospholipase inhibitor, specifically targeting neutral sphingomyelinase 2 (nSMase2). This compound effectively reduces tau-induced nSMase2 activity and mitigates ceramide elevation, thereby slowing tau propagation in mouse models. PDDC is utilized in research related to Alzheimer's disease, providing insights into the modulation of neurodegenerative pathways. -
rPLA/cPLA Inhibitor
EA4 is a quinone derivative that acts as an inhibitor of both secretory and cytosolic phospholipase A2 (rPLA and cPLA). It exhibits rPLA2 inhibition with a Ki value of 130 μM, making it a valuable tool for investigating the mechanisms of hemostasis, thrombosis, and erythropoiesis. This compound aids in the study of lipid metabolism and its implications in various physiological and pathological processes. -
PLCδ1 Inhibitor
N-Stearoylsphingomyelin is a sphingolipid that acts as an inhibitor of Phospholipase Cδ1 (PLCδ1). This compound plays a significant role in modulating cellular signaling pathways and is valuable in studying the physiological effects of PLCδ1 inhibition. Its applications include research in cell biology, signal transduction, and neurobiology, making it a useful reagent for investigating various biological processes. -
sPLA2-IIA Inhibitor
Ochnaflavone is a potent inhibitor of IIA-type secretory phospholipase A2 (sPLA2-IIA) with an IC50 value of 3.45 µM. It demonstrates notable anti-inflammatory and hepatoprotective properties, effectively inhibiting both phosphatidylethanolamine (PE) degradation and carbon tetrachloride (CCl4)-induced lipid peroxidation in rat liver, with an IC50 of 7.16 µM for lipid peroxidation. Ochnaflavone is valuable in research related to liver injury and inflammatory conditions. -
sPLA Inhibitor
LY433771 is a selective inhibitor of type X secretory phospholipase A2 (sPLA2), exhibiting an IC50 value of 3 nM. This compound is valuable for research applications focused on cardiovascular diseases, facilitating the investigation of sPLA2's role in lipid metabolism and inflammatory processes. Its potent inhibition makes it a crucial tool for understanding the underlying mechanisms of cardiovascular pathologies. -
sPLA2 Inhibitor
(Z)-Oleyloxyethyl phosphorylcholine is a selective inhibitor of secreted Phospholipase A2 (sPLA2), an enzyme that plays a crucial role in the production of proinflammatory lipid mediators. This compound is valuable for investigating inflammatory diseases and their underlying mechanisms. Additionally, (Z)-OPC has been shown to modify red blood cell membranes and can be utilized in the development of oxygen-carrying liquids, such as perfluorocarbons, for applications in reducing toxin-induced hemolysis. -
cPLA2α Inhibitor
Efipladib is a selective inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 0.04 μM and a Kd of 0.067 μM. This compound demonstrates significant inhibition of arachidonic acid release, contributing to its potential in modulating inflammatory responses. Efipladib is valuable for research applications aimed at understanding cPLA2α-driven pathways in various disease models, including neuroinflammation and cardiovascular conditions. -
PLA2 Inhibitor
MJ33-OH lithium is a metabolite of MJ33 and serves as a specific inhibitor of phospholipase A2 (PLA2). Acting as a competitive and reversible inhibitor, MJ33-OH lithium effectively blocks the activity of calcium-independent phospholipase A2 (iPLA2), particularly in the context of Prdx6. This compound is valuable for research applications focused on inflammation, cellular signaling, and lipid metabolism. -
PLD2 Inhibitor
VU 0364739 hydrochloride is a selective inhibitor of phospholipase D2 (PLD2), exhibiting an IC50 of 20 nM for PLD2 while having significantly lower activity against PLD1 (IC50 of 1500 nM). This compound has been shown to induce apoptosis, making it a valuable reagent for cancer research. Its specificity and potent biological activity position VU 0364739 as an important tool for studying PLD2's role in cellular processes and cancer pathophysiology. -
Phospholipases A Inhibitor
ROC-0929 is a potent and selective inhibitor of secreted phospholipases A2 (sPLA2s), specifically targeting hGX with an IC50 of 80 nM. By inhibiting the phosphorylation of ERK1/2 and p-38, ROC-0929 demonstrates significant anti-inflammatory activity. This compound holds promise for investigating the role of sPLA2s in inflammation-related diseases, making it a valuable tool for research in this area. -
Phospholipase Inhibitor
Ecopladib is a selective inhibitor of cytosolic phospholipase A2α (cPLA2α), exhibiting sub-micromolar potency with IC50 values of 0.15 μM and 0.11 μM in GLU micelle and rat whole blood assays, respectively. This compound effectively modulates the release of arachidonic acid and subsequent eicosanoid synthesis, making it a valuable tool for studying inflammatory processes. Ecopladib is applicable in research focused on the mechanisms of inflammation and related pathways. -
GVIA iPLA2 Inhibitor
FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). It exhibits significant biological activity by modulating phospholipid metabolism, making it a valuable tool for studying ovarian cancer and neurological disorders, including peripheral nerve injury and multiple sclerosis. Researchers can utilize FKGK11 to explore the roles of iPLA2 in disease mechanisms and therapeutic interventions. -
GVIA iPLA2 Inhibitor
GK187 is a potent and selective inhibitor of Group VIA calcium-independent phospholipase A2 (GVIA iPLA2), exhibiting an XI(50) value of 0.0001. This compound demonstrates significant biological activity and potential for research in various neurological disorders, allowing for deeper insights into phospholipid metabolism and its implications in neurobiology. Its selectivity makes it a valuable tool for investigating the roles of GVIA iPLA2 in cellular processes and disease mechanisms. -
sPLA2 Inhibitor
AZD2716 is a selective inhibitor of secretory phospholipase A2 (sPLA2), specifically targeting sPLA2-IIa, sPLA2-V, and sPLA2-X with IC50 values of 10 nM, 40 nM, and 400 nM, respectively. By effectively reducing pro-inflammatory lipid production, AZD2716 diminishes macrophage activation and foam cell formation. This compound is valuable for investigating the pathways involved in atherosclerosis and various inflammatory diseases linked to sPLA2 activity. -
iPLA2γ Inhibitor
(R)-Bromoenol lactone is an irreversible chiral inhibitor targeting calcium-independent phospholipase γ (iPLA2γ). It exhibits potent inhibition of human recombinant iPLA2γ, with an IC50 value of approximately 0.6 µM. This compound is significant for research applications involving lipid signaling, inflammatory responses, and cellular metabolism. -
PLD Inhibitor
FIPI hydrochloride is a potent inhibitor of phospholipase D (PLD), exhibiting an IC50 of approximately 25 nM for both PLD1 and PLD2. This compound plays a critical role in regulating cytoskeletal reorganization, cell migration, and chemotactic responses, making it valuable for cancer research. Additionally, FIPI hydrochloride enhances the secretion and aggregation of platelet dense granules, contributes to thrombosis inhibition, reduces infarct volume in ischemic stroke models, and promotes recovery of neuronal function. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-2 is a potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), exhibiting an IC50 of 120 nM for recombinant human Lp-PLA2. This small molecule plays a significant role in modulating lipid metabolism and inflammatory processes associated with cardiovascular disease. It is valuable for research applications focused on understanding the biological implications of Lp-PLA2 in various pathophysiological conditions. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-5 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme implicated in the hydrolysis of lipoprotein and phospholipids. This compound demonstrates significant potential in research focused on various diseases related to Lp-PLA2 activity, including atherosclerosis and Alzheimer's disease. Its inhibition of Lp-PLA2 may provide insights into therapeutic strategies for managing lipid-related pathologies. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that plays a crucial role in the hydrolysis of lipoprotein lipids and phospholipids. This compound is valuable for investigating the biological effects of Lp-PLA2 in various pathological conditions, including atherosclerosis and Alzheimer's disease. Research applications include elucidating the enzyme's role in lipid metabolism and inflammation pathways. -
Phospholipase A2 Iinhibitor
Plipastatin A1 is a lipopeptide that serves as an inhibitor of phospholipase A2. It demonstrates significant inhibitory effects on the conidial germination of Botrytis cinerea, leading to a reduction in the occurrence of gray mold on tomato leaves. This compound is valuable for research focused on agricultural pathogens and plant protection strategies against gray mold disease. -
PLD Inhibitor
VU0155069 hydrochloride is a potent and selective inhibitor of phospholipase D (PLD), with IC50 values of 46 nM for PLD1 and 933 nM for PLD2. This compound effectively inhibits the migration of both human and mouse breast cancer cell lines, making it a valuable tool for studying the role of PLD in cancer biology. Its unique mechanism of action allows researchers to explore therapeutic strategies targeting PLD-related pathways in oncology. -
Lp-PLA2 Inhibitor
SB-435495 hydrochloride is a highly potent and selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), characterized by its reversible and non-covalent action. With an IC50 value of 0.06 nM, it demonstrates significant inhibitory efficacy, making it a valuable tool for research into cardiovascular diseases and inflammatory conditions. This compound is suitable for studies focused on the role of Lp-PLA2 in atherosclerosis and other lipid metabolism-related disorders. -
LYPLA1/LYPLA2 Inhibitor
ML378 is a dual inhibitor of LYPLA1 and LYPLA2, demonstrating IC50 values of 122 nM and 245 nM, respectively. In addition, ML378 exhibits potent inhibition of ABHD6 with an IC50 of 3.15 nM. This compound is valuable for investigating the physiological and pathological roles of LYPLA1 and LYPLA2 in various biological processes and disease models. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme involved in the hydrolysis of lipoprotein lipids. This compound demonstrates significant biological activity, making it a valuable tool for exploring the role of Lp-PLA2 in various pathological conditions, including atherosclerosis and Alzheimer’s disease. Lp-PLA2-IN-11 is suitable for research applications focused on the modulation of lipoprotein metabolism and the investigation of Lp-PLA2's contribution to disease progression. -
nSMase2 Inhibitor
DPTIP-prodrug 18 is an orally active prodrug that demonstrates high brain penetrability and functions as a potent nSMase2 inhibitor. It effectively inhibits IL-1β-induced release of extracellular vesicles by targeting and inhibiting the activity of neutral sphingomyelinase-2. This compound is suitable for research in brain injury studies, providing insights into the molecular mechanisms of neuroinflammation and extracellular signaling. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-9 is a tetracyclic pyrimidinone compound that functions as a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), exhibiting a pIC50 of 10.1 for recombinant human Lp-PLA2. This compound demonstrates significant biological activity that may be valuable in the study of neurodegenerative diseases and related pathologies, making it a useful tool for research aimed at understanding Lp-PLA2's role in neuroinflammation and its therapeutic potential. -
PLA2 Inhibitor
Ikshusterol 3-O-glucoside is a potent phospholipase A2 (PLA2) inhibitor derived from plant sources. This compound exhibits significant biological activity by effectively modulating inflammatory responses associated with PLA2 activity. Its applications in research include studying snake venom toxicity and exploring anti-inflammatory pathways, making it a valuable tool for investigations into immune response and venom pharmacology. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-17 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound is utilized in research to investigate the role of Lp-PLA2 in the hydrolysis of oxidized lipids, leading to the production of inflammatory mediators. Lp-PLA2-IN-17 is valuable in studying various inflammatory disorders and cardiovascular diseases linked to lipid metabolism. -
cPLA2 Inhibitor
AX048 is a selective inhibitor of calcium-dependent phospholipase A2 (cPLA2), exhibiting a potent inhibitory effect with an XI(50) of 0.022 mole fraction. This compound demonstrates significant antihyperalgesic efficacy, making it a valuable tool for research into pain mechanisms and inflammatory pathways. AX048 is applicable in studies focusing on neuropathic pain and the modulation of lipotoxicity-related conditions. -
cPLA2 Inhibitor
BMS-229724 is a potent, orally active inhibitor of cytosolic phospholipase A2 (cPLA2), exhibiting an IC50 of 2.8 μM. This compound effectively inhibits the production of arachidonic acid and eicosanoids in various cell types, including U937 cells, neutrophils, and platelets. With demonstrated anti-inflammatory properties, BMS-229724 is valuable for research into skin inflammation and related inflammatory diseases. -
cPLA2α Inhibitor
WAY-196025 is a selective, orally active inhibitor of cytosolic phospholipase A2 alpha (cPLA2α) with an IC50 of 0.01 μM and a Kd of 0.013 μM. This compound effectively inhibits the production of inflammatory mediators, including prostaglandins and leukotrienes, which are crucial in inflammatory responses. WAY-196025 is valuable for research applications in inflammation and immunology, particularly in studies related to asthma and other inflammatory diseases. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme involved in the hydrolysis of lipoprotein lipids and phospholipids. This compound exhibits significant biological activity in the context of neurodegenerative diseases, including Alzheimer's disease, as well as ophthalmic conditions such as glaucoma and age-related macular degeneration. Additionally, Lp-PLA2-IN-10 may have implications in cardiovascular research, particularly in relation to atherosclerosis. -
Lp-PLA2 Inhibitor
ML256 is a covalent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), a key enzyme involved in lipid metabolism and inflammation. This compound exhibits biological activity by selectively targeting Lp-PLA2, making it valuable in the investigation of neoplasms with constitutively active variants of KRAS or HRAS. It is useful for research applications focusing on cancer biology and the modulation of inflammatory pathways. -
Bee Venom Phospholipase A2 Inhibitor
AGN-190383 is a potent inhibitor of bee venom phospholipase A2, targeting key enzymes involved in inflammatory processes. It effectively inhibits both hormone-operated and depolarization-dependent calcium mobilization, as well as fMLP-stimulated increases in free cytosolic calcium levels. Due to its ability to modulate calcium signaling and exhibit anti-inflammatory activity, AGN-190383 is valuable for research applications in studying inflammation and calcium-related cellular responses. -
Phospholipase A2 Inhibitors
Ro 23-9358 is a selective inhibitor of secretory phospholipase A2, known for its potent anti-inflammatory properties. By targeting this enzyme, Ro 23-9358 modulates the release of pro-inflammatory lipid mediators, making it a valuable tool in studying inflammatory pathways. Its application is relevant in research focused on inflammatory diseases and the development of therapeutic strategies to mitigate inflammation. -
ASM Inhibitor
ASM-IN-2 is a potent inhibitor of acid sphingomyelinase (ASM), exhibiting an IC50 value of 0.87 μM. This compound plays a crucial role in reducing ceramide levels, which is linked to various antidepressant mechanisms of action. Notably, ASM-IN-2 demonstrates significant antidepressant effects in the chronic unpredictable mild stress (CUMS) mouse model, making it an important tool for research in the development of antidepressant therapies. -
RBBP9 Inhibitor
ML114 is a selective inhibitor of the serine hydrolase RBBP9, exhibiting an IC50 of 0.63 μM against recombinant RBBP9. This compound has been shown to suppress the proliferation of human pluripotent stem cells (hPSCs) by modulating the expression of NFYA and other associated factors, without triggering differentiation. ML114 is valuable for research in cancer pathology, particularly in the study of retinoblastoma. -
sPLA2-IIA Inhibitor
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK, specifically designed to target human Group IIA phospholipase A2 (hGIIA). This compound effectively binds to hGIIA, inhibiting its enzymatic activity and preventing the hydrolysis of glycerophospholipids. This inhibition leads to decreased production of free fatty acids, such as arachidonic acid, making it a valuable tool for studying inflammatory processes and lipid metabolism in various biological models. Its application is particularly relevant in research aimed at understanding related pathophysiological conditions. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-6 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with an exceptional pIC50 of 10.0 against recombinant human Lp-PLA2. This tetracyclic pyrimidinone compound is primarily utilized in research focusing on neurodegenerative diseases, where its biological activity may contribute to a deeper understanding of disease mechanisms and the development of therapeutic strategies. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-12 is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound has shown potential in the study of neurodegenerative diseases such as Alzheimer's disease, as well as ocular conditions like glaucoma and age-related macular degeneration. Additionally, Lp-PLA2-IN-12 is relevant for research on cardiovascular diseases, including atherosclerosis, by modulating inflammatory processes associated with these conditions. -
Phospholipase A2 Inhibitor
Folipastatin is a potent inhibitor of phospholipase A2, demonstrating an IC50 value of 39 μM. This novel depsidone compound, derived from Aspergillus unguis, exhibits significant biological activity, making it a valuable tool for studies related to phospholipid metabolism and inflammatory processes. Its application extends to research on lipid signaling pathways and related cellular mechanisms. -
SMS2 Inhibitor
SMS2-IN-3 is a potent and selective inhibitor of sphingomyelin synthase 2 (SMS2) with an IC50 of 2.2 nM. This compound significantly reduces hepatic sphingomyelin (22:0) levels, making it a valuable tool for research into sphingolipid metabolism and its implications in various metabolic disorders. SMS2-IN-3 is applicable in studies exploring the role of sphingolipids in health and disease. -
Sphingomyelinase Inhibitor
SM (d18:1/15:0) is an inhibitor of sphingomyelinase, a crucial enzyme involved in sphingolipid metabolism. This compound demonstrates potential in the study of neurodegenerative diseases such as Alzheimer's and metabolic syndrome. Its mechanism of action makes it a valuable tool for investigating the roles of sphingolipids in various cellular processes and disease states. -
HSF-PLA2 Inhibitor
Luffariellolide is a potent inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2), with an IC50 value of 5 μM. This compound has demonstrated significant anti-inflammatory activity, evidenced by its ability to effectively inhibit phorbol ester (PMA)-induced ear edema, with an ED50 of 50 μg/ear. Luffariellolide is a valuable tool for research applications focused on inflammation and lipid metabolism. -
PLA2 Inhibitor
MJ33-OH is a metabolite of MJ33, functioning as a specific, competitive, and reversible inhibitor of phospholipase A2 (PLA2). This compound effectively inhibits the activity of calcium-independent phospholipase A2 (iPLA2), particularly in the context of Prdx6 regulation. MJ33-OH is valuable for research applications focused on studying PLA2-related pathways and its implications in various biochemical processes. -
Lp-PLA2 Inhibitor
Lp-PLA2-IN-15 is a selective inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). This compound exhibits potent inhibitory activity, making it valuable for investigating the role of Lp-PLA2 in various biological processes. It is particularly relevant in Alzheimer's disease research and other studies related to inflammation and lipid metabolism.
